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Abstract
Pandemic H1N1 influenza A (H1N1pdm) is currently a dominant circulating influenza strain worldwide. Severe cases of
H1N1pdm infection are characterized by prolonged activation of the immune response, yet the specific role of inflammatory
mediators in disease is poorly understood. The inflammatory cytokine IL-6 has been implicated in both seasonal and severe
pandemic H1N1 influenza A (H1N1pdm) infection. Here, we investigated the role of IL-6 in severe H1N1pdm infection. We
found IL-6 to be an important feature of the host response in both humans and mice infected with H1N1pdm. Elevated
levels of IL-6 were associated with severe disease in patients hospitalized with H1N1pdm infection. Notably, serum IL-6
levels associated strongly with the requirement of critical care admission and were predictive of fatal outcome. In C57BL/6J,
BALB/cJ, and B6129SF2/J mice, infection with A/Mexico/4108/2009 (H1N1pdm) consistently triggered severe disease and
increased IL-6 levels in both lung and serum. Furthermore, in our lethal C57BL/6J mouse model of H1N1pdm infection,
global gene expression analysis indicated a pronounced IL-6 associated inflammatory response. Subsequently, we examined
disease and outcome in IL-6 deficient mice infected with H1N1pdm. No significant differences in survival, weight loss, viral
load, or pathology were observed between IL-6 deficient and wild-type mice following infection. Taken together, our
findings suggest IL-6 may be a potential disease severity biomarker, but may not be a suitable therapeutic target in cases of
severe H1N1pdm infection due to our mouse data.
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Introduction
Influenza is an acute viral infection of the respiratory tract
caused by influenza type A, B, and C viruses of the Orthomyxoviridae
family [1]. Influenza is typically spread through seasonal or
sporadic epidemics, but the periodic emergence of novel influenza
strains can result in widespread pandemics capable of extensive
morbidity and mortality. In early 2009 pandemic H1N1 influenza
A (H1N1pdm), a novel influenza A H1N1 strain of swine-origin,
emerged from Mexico and rapidly spread worldwide [2]. Although
PLoS ONE | www.plosone.org 1 June 2012 | Volume 7 | Issue 6 | e38214the pandemic period of H1N1pdm has now passed [3], H1N1pdm
remains a dominant circulating influenza strain in various parts of
the world.
Infection with H1N1pdm has resulted in diverse clinical
outcomes. The vast majority of reported cases have been mild
and self-limiting [4–6]; typical symptoms have included fever, sore
throat, malaise, and headache [6,7]. However, a subset of cases
have been characterized by serious illness, often requiring
hospitalization and mechanical ventilator support [2,6,8,9].
Common complications in such severe cases of H1N1pdm
infection have included: severe hypoxemia, shock, pneumonia,
and acute respiratory distress syndrome (ARDS) [2,8,9]. Non-
pulmonary acute organ dysfunction has also been reported [9,10].
Importantly, the triggers for severe illness are not completely
understood and the host immune response to H1N1pdm infection
remains to be comprehensively characterized.
Inflammation is a rapid and non-specific host defense mecha-
nism against infection that is tightly regulated by a network of
inflammatory mediators, which includes cytokines such as in-
terleukin-6 (IL-6) [11–13]. IL-6 is a pleiotropic cytokine signifi-
cantly implicated in various facets of the immune response,
including a prominent role in inflammation. IL-6 is the chief
mediator of the acute phase response and fever [14]. IL-6 also has
important involvement in many pathogenic inflammatory states:
IL-6 levels are elevated and correlate with sepsis severity and
mortality [15] and IL-6 has been implicated in the cytokine storm
following avian influenza A H5N1 and severe acute respiratory
syndrome (SARS) infection [16–18]. In contrast, studies have also
shown that IL-6 may play roles in regulating and limiting
inflammation, with mice deficient for IL-6 displaying more
pronounced inflammation and neutrophilia in response to aero-
solized endotoxin [19]. Within the context of the lung, IL-6
promotes pulmonary inflammation and IL-6 levels correlate with
severity and mortality of ARDS [20,21].
IL-6 levels have been associated with symptom duration and
severity in cases of seasonal influenza infection [22–24]. Recently,
increased IL-6 expression was observed in severe cases of
H1N1pdm infection, with a significant inverse association between
IL-6 and arterial oxygen levels in patients hospitalized with
H1N1pdm infection [25]. Given the known involvement of IL-6 in
pathogenic lung inflammation, we sought to investigate the role of
IL-6 in severe H1N1pdm infection, and potential contributions to
disease. Here, we report increased IL-6 expression in both humans
hospitalized with H1N1pdm infection and in multiple mice strains
infected with H1N1pdm (A/Mexico/4108/2009 (H1N1pdm)),
which implicated IL-6 in the host response to H1N1pdm infection.
We then explored the effect of IL-6 deficiency on disease in
H1N1pdm infected IL-62/2 mice. Our results indicated that IL-
6 expression was strongly associated with disease severity although
loss of IL-6 did not alter disease outcome in mice. This suggested
IL-6 as a marker of severe influenza H1N1pdm disease but not
a potential therapeutic target which has important implications on
the design and administration of influenza A therapeutics.
Results
Serum IL-6 Levels Associate Strongly with Disease
Severity in Patients Hospitalized with H1N1pdm Infection
Increased IL-6 expression has been reported following seasonal
influenza infection, as well as in severe cases of H1N1pdm
infection [22–25]. We investigated IL-6 expression in humans
hospitalized with H1N1pdm infection and further analyzed
patient outcome with clinical signs. A total of 45 hospitalized
patients with laboratory-confirmed H1N1pdm infection were
included in our analysis. Serum samples were collected within
48 hours of hospital admission and IL-6 protein concentrations
were measured. IL-6 concentrations were found to be significantly
higher in patients who required critical care support (n=35)
compared to patients who did not (n=10) (Figure 1A). Also, IL-6
concentrations were higher in patients who died (n=10) compared
to survivors (n=35), although differences were not statistically
significant (p=0.065) (Figure 1B). Binary logistic regression (BLR)
analysis demonstrated that levels of IL-6 (log10 IL-6 (pg/mL))
adjusted by age and sex were significantly associated with
increased risk of fatal outcome [Odds Ratio (95% Confidence
Interval); p-value]: [2.63 (1.06–6.49); 0.036]. Taken together,
these results revealed a strong association of IL-6 patient
concentration to disease severity in people hospitalized with
H1N1pdm infection.
Severe H1N1pdm Infection Triggers Increased IL-6
Expression in mice
Our human clinical data implicated IL-6 in H1N1pdm
infection. We next investigated IL-6 expression in mouse models
of severe H1N1pdm infection. To observe possible strain variation
[26], we infected three mouse strains, C57BL/6J mice (n=17),
BALB/cJ mice (n=17), and B6129SF2/J mice (n=17), intransally
with 10
4 EID50 A/Mexico/4108/2009 (H1N1pdm), and observed
survival, weight loss, and IL-6 expression for fourteen days pi.
H1N1pdm infection caused severe disease in mice of all three
groups (Figure 2A). Dramatic declines in weight were observed as
of day 3 post-infection (pi) through to days 7–8 pi, with reductions
in percent survival as of day 5 pi. Final percent survival was 36.4%
(4/11), 18.2% (2/11), and 0% (0/11) for C57BL/6J, BALB/cJ,
and B6129SF2/J mice, respectively. Interestingly, weight loss in
BALB/cJ mice slowed slightly at days 5–6 pi, delaying drops in
percent survival by one day relative to C57BL/6J and B6129SF2/
J mice. Yet, no significant differences in survival curves were
observed (a=0.05). Similar viral loads were detected in the lungs
of infected mice at day 3 pi.
We next evaluated Il6 gene regulation at the mRNA level
following H1N1pdm infection. Total RNA was extracted from
lung homogenates and assayed by quantitative real-time RT-PCR
(qRT-PCR) for fold changes in Il6 mRNA expression at days 0, 3,
and 5 pi (n=3). At both day 3 and 5 pi, Il6 mRNA was
significantly increased in the lungs of all mouse strains following
H1N1pdm infection (Figure 2B) peaking on day 3 pi. No
significant differences were seen among the mouse groups on
day 3, although significant differences were seen day 5 pi between
C57BL/6J and BALB/cJ mice.
To measure IL-6 cytokine protein levels, lung homogenates and
serum were collected at days 0 and 5 pi, n=3 at each time-point.
Dramatic increases in IL-6 cytokine levels were observed at day
5 pi (Figure 2C). Among the three groups, BALB/cJ mice were the
weakest producers of IL-6 in both serum and lung. Serum IL-6
protein levels were significantly higher in C57BL/6J mice than in
BALB/cJ mice. Similarly, C57BL/6J mice had higher lung IL-6
protein levels than BALB/cJ mice, although differences were not
statistically significant (p=0.063). No significant differences in IL-
6 protein levels were observed in B6129SF2/J mice in relation to
C57BL/6J or BALB/cJ mice, with p-values .0.10 in all cases.
Levels of proinflammatory cytokines tumor necrosis factor alpha
(TNF-a) and monocyte chemotactic protein-1 (MCP-1) were also
increased following infection, with no significant differences
between groups (data not shown). Taken together, our results
revealed similar disease severity in C57BL/6J, BALB/cJ, and
B6129SF2/J H1N1pdm infected mice. Furthermore, increased IL-
6 expression was consistently observed in all groups, suggesting an
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PLoS ONE | www.plosone.org 2 June 2012 | Volume 7 | Issue 6 | e38214Figure 1. IL-6 levels associated strongly with disease severity in patients hospitalized with H1N1pdm infection. Serum IL-6 levels in
hospitalized patients with laboratory-confirmed H1N1pdm infection. Comparison between different groups: between patients requiring critical
(n=35) or non-critical (n=10) care (A) and between patients who survived (n=35) or died (n=10) (B). Mann-Whitney U test was applied to assess
statistical significance of differences between groups; p-values ,0.05 are indicated by an asterisk (*).
doi:10.1371/journal.pone.0038214.g001
Figure 2. Severe A/Mexico/4108/2009 (H1N1pdm) infection triggered increased IL-6 expression in C57BL/6J, BALB/cJ, and
B6129SF2/J mice. Survival curves for C57BL/6J (closed squares), BALB/cJ (grey squares), and B6129SF2/J (open squares) mice infected intranasally
with 10
4 EID50 A/Mexico/4108/2009 (H1N1pdm). n=11 for all three groups. The logrank test (a=0.05) was used to ascertain significance in
differences in survival (Ai) [43]. Average weight curve for C57BL/6J (closed diamonds), BALB/cJ (grey diamonds), and B6129SF2/J (open diamonds)
mice. Vertical error bars indicate 61 standard deviation. n=17 for all groups. Asterisks below the curves indicate significant difference between
C57BL/6J weights and BALB/cJ weights, asterisks above the curves indicate significant difference between C57BL/6J weights and B6129SF2/J weights.
No significant differences between BALB/cJ and B6129SF2/J weights (Aii). Viral load in lung homogenates collected at days 0 and 3 pi. n=3 for all
groups. Infection of Madin-Darby Canine Kidney cells was employed to measure viral titers. The assay had a limit of detection of 10
1.75 TCID50/g of
lung tissue, indicated by the dashed line. Vertical error bars indicate +1 standard deviation (Aiii). Il6 mRNA expression profiling in lung homogenates
by qRT-PCR. Results are expressed as fold changes over expression in uninfected day 0 pi controls. n=3 for each group. Vertical error bars indicate +1
standard deviation. (B). IL-6 expression levels in serum and lung homogenates. n=3 for each group. Vertical error bars indicate +1 standard deviation
(Ci&ii). The two-tailed, two-sample unequal variances Student’s t-test was used to ascertain significance (p-value ,0.05=*, p-value ,0.01=**, p-value
,0.001=***).
doi:10.1371/journal.pone.0038214.g002
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backgrounds.
C57BL/6J mice Elicit IL-6 Associated Inflammatory
Response to H1N1pdm Infection
We observed increased IL-6 levels in response to severe
H1N1pdm infection in mice. This led us to investigate by
functional genomics the impact of IL-6 on the inflammatory
response during H1N1pdm infection. C57BL/6J mice were
infected intranasally with a lethal dose (10
5 EID50)o fA /
Mexico/4108/2009 (H1N1pdm) (Figure S1). Lung homogenates
from infected animals were collected daily for RNA extraction and
subsequent analysis of gene expression from days 0 to 6 pi, n=3 at
each time point.
Statistical analysis of gene expression data by Extraction of
Differential Gene Expression (EDGE) software identified 7,803
probes for significantly differentially regulated genes. Hierarchical
clustering by Pearson’s correlation revealed several groups of co-
ordinately expressed genes. Functional classification with In-
genuity Pathway Analysis v9.0 (IPA) delineated three prominent
functional clusters: cell growth and metabolism, interferon re-
sponse, and inflammatory response (Figure 3A). The cell growth
and metabolism cluster was characterized by a gradual decline in
gene expression over the course of infection. The interferon and
inflammatory response clusters were both rapidly upregulated
following infection: by day 2 pi, expression of the majority of genes
in both clusters had measurably increased. However, while
expression levels of interferon response genes had increased early
and subsequently stabilized by day 3 pi, inflammatory response
gene expression levels increased more gradually and stabilized
later than day 3 pi. Within the inflammatory response cluster was
a group of genes distinguishable for markedly increased expres-
sion. Functional analysis with IPA revealed genes associated with
multiple inflammatory pathways regulated by interleukin-1b (IL-
1b) and IL-6. Global microarray expression analysis displayed
hallmarks of the early host response to viral infection and
highlighted the prominent and rapid IL-1b/IL-6 mediated
response.
To evaluate the status of IL-6 signalling during infection,
associated genes as determined by IPA were investigated
(Figure 3Bi). Early in infection, downstream signalling machinery,
most notably IL-6 binding receptor subunit alpha (Il6ra) and
intracellular signal transducer and activator of transcription 3
(Stat3), were upregulated, with peak upregulation observed at day
2 pi. This preceded upregulation of Il6, of which expression
plateaued only by day 3 pi. IL-6 inducible negative regulator of
Janus kinase 2 (Jak2), suppressor of cytokine signalling 1 (Socs1),
was upregulated late following infection, at day 6 pi. Meanwhile,
mitogen-activated protein kinase 3 (Mapk3) and serum response
factor (Srf) were persistently downregulated throughout infection.
Visual representation of the IL-6 signalling pathway reported by
IPA at day 3 pi revealed upregulation of the JAK-STAT3 axis of
IL-6 signalling, while the extracellular-signal-regulated-kinase
(ERK)-mediated axis was downregulated (Figure 3Bii). Comple-
mentary analysis of Il6, Stat3, and Il6ra gene expression by qRT-
PCR similarly identified peak upregulation of Stat3 and Il6ra early
at day 2 pi, and persistent upregulation of Il6 throughout infection
(Figure 3C). Genes associated with JAK-STAT3-mediated IL-6
signalling were upregulated early and throughout infection.
IL-6 has diverse functions, among which is positive regulation of
the acute phase response [14]. To verify functional signalling by
IL-6, the expression status of genes associated with the acute phase
response was assessed. Using DAVID Bioinformatics Resource
v6.7 [27,28], multiple functional classifications, most notably Gene
Ontology Biological Process, Panther, and Kyoto Encyclopaedia
of Genes and Genomes were used to identify functionally related
gene networks from all 7,803 probes for significantly differentially
regulated genes. Gene Ontology Biological Process classification
GO:0002526– acute inflammatory response was selected as
a suitable representation of acute phase response effector genes;
the network was upregulated throughout infection (Table S1).
Results were consistent amongst all classification systems (data not
shown). Complementary analysis by qRT-PCR of known IL-6-
inducible genes orosomucoid 2 (Orm2), serum amyloid A 3 (Saa3),
serum amyloid A 4 (Saa4), Socs1, and suppressor of cytokine
signalling 3 (Socs3) confirmed increased IL-6- inducible gene
expression (Figure 3C).
Analysis of gene expression data in a lethal mouse model of
H1N1pdm revealed a cluster of co-ordinately expressed genes
associated with IL-1b/IL-6 mediated inflammation, identified
upregulation of genes responsible for IL-6 JAK/STAT3-mediated
signalling, and confirmed increased IL-6 signalling with observed
increases in expression of known IL-6-regulated pathways. These
results suggested a prominent role for IL-6 associated inflamma-
tion in the host response to H1N1pdm infection in C57BL/6J
mice.
IL-6 Deficiency does not Significantly Impact H1N1pdm
Infection Outcome in Mice
Increased IL-6 expression in both patients hospitalized with
H1N1pdm and mouse models of H1N1pdm implicated IL-6 in the
host response to infection. Given the known proinflammatory
properties of IL-6 [20,21], we hypothesized that IL-6 may play
a pathogenic role in H1N1pdm infection. Thus, abrogation of IL-
6 would reduce symptom severity and improve clinical outcome.
Wild-type C57BL/6J (IL-6 wild-type) mice (n=22) and IL-62/2
mice (n=34) were infected intranasally with 10
4 EID50 A/
Mexico/4108/2009 (H1N1pdm), and observed for fourteen days
pi.
IL-6 wild-type and IL-62/2 mice both exhibited severe illness
following infection (Figure 4A). As of day 5 pi, weight loss in both
groups resulted in marked decreases in survival. Percent survival
levelled by day 9 pi at approximately 14% and 12% for IL-6 wild-
type and IL-62/2 mice, respectively. Differences in survival and
weight curves were not statistically significant (a=0.05) between
IL-62/2 and IL-6 wild-type mice. However, IL-62/2 mice
tended to lose weight faster than IL-6 wild-type mice, causing IL-
62/2 percent survival to drop one day prior to IL-6 wild-type
percent survival. For both groups weight loss was observed until
days 6–7 pi, followed by a recovery phase. Of the surviving mice,
IL-6 wild-type (n=3/22) and IL-62/2 mice (n=3/34) recovered
weights to near 100% and 95%, respectively. Taken together,
these data showed no significant differences in the clinical outcome
of H1N1pdm infected IL-6 wild-type and IL-62/2 mice.
To evaluate the effect IL-6 deficiency on viral load in the host,
lung tissues were collected and homogenized day 3 pi, and viral
loads were measured (Figure 4B). Average viral loads (n=3) were
10
7.2 and 10
6.9 tissue culture infectious dose (TCID)50/g for IL-6
wild-type and IL-62/2 mice, respectively. Differences in viral
loads were not statistically distinguishable (a=0.05), although IL-
62/2 mice did exhibit slightly lower viral loads.
To identify pathological differences resulting from IL-6 de-
ficiency, lung tissues were collected at days 3 and 6 pi and
examined (Figure 4C). At day 3 pi, both IL-6 wild-type and IL-
62/2 exhibited alveolar thickening and minimal infiltration, with
more infiltration observed in IL-62/2 mice. By day 6 pi, alveolar
thickening was more prominent and infiltration more pronounced
in both groups where the lung tissues were not markedly
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PLoS ONE | www.plosone.org 4 June 2012 | Volume 7 | Issue 6 | e38214Figure 3. C57BL/6J mice elicited IL-6 associated inflammatory response to A/Mexico/4108/2009 (H1N1pdm) infection. Global gene
expression profiling in lungs of C57BL/6J mice infected intranasally with 10
5 EID50 A/Mexico/4108/2009 (H1N1pdm). Probes for significantly
differentially expressed genes were subjected to one-way hierarchical clustering analysis (Pearson’s correlation). The most significant gene networks
(Inflammatory Response, Cell Growth and Metabolism) or most prominent represented canonical pathways (IL-1 and IL-6-mediated Inflammation,
Interferon Response), as determined by IPA, are indicated for each cluster (A). Expression data of genes associated with IL-6 signalling, as determined
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PLoS ONE | www.plosone.org 5 June 2012 | Volume 7 | Issue 6 | e38214by IPA, profiled over the course of infection (Bi). Visual representation of IL-6 signalling pathway, as represented by IPA, at day 3 pi. Overlaid colors
represent gene regulation status; upregulated genes are red, downregulated genes are blue. Color intensity correlates with the magnitude of change
in gene expression (Bii). Gene expression data validation by qRT-PCR for Il6, IL-6 signalling genes Stat3 and Il6ra, and IL-6 response genes Orm2, Saa3,
Saa4, Socs1, and Socs3. Results are expressed as fold changes over expression in non-infected controls. Reported values for each time point are the
average of three samples with +1 standard deviation indicated by vertical error bars. N.I. indicates non-infected controls. The two-tailed, two-sample
unequal variances Student’s t-test was used to ascertain significance (p-value ,0.05=*, p-value ,0.01=**) (C).
doi:10.1371/journal.pone.0038214.g003
Figure 4. Loss of IL-6 expression in IL-62/2 mice did not significantly impact disease severity following A/Mexico/4108/2009
(H1N1pdm) infection. Survival curves for IL-6 wild-type (closed squares) and IL-62/2 (open squares) mice infected intranasally with 10
4 EID50 A/
Mexico/4108/2009 (H1N1pdm). n=34 for IL-62/2 mice and n=22 for IL-6 wild-type mice. The logrank test (a=0.05) was used to ascertain
significance in differences in survival (Ai) [43]. Average weight curve for IL-6 wild-type (closed diamonds) and IL-62/2 (open diamonds) mice. Vertical
error bars indicate 61 standard deviation. The two-tailed, two-sample unequal variances Student’s t-test was used to ascertain significance (p-value
,0.05=*). n=40 for IL-62/2 mice and n=35 for IL-6 wild-type mice (Aii). Viral load in lung homogenates of IL-62/2 and IL-6 wild-type mice. Lung
tissue collected at day 3 pi. n=3 for IL-62/2 mice and n=3 for IL-6 wild-type mice. Vertical error bars indicate +1 standard deviation. The two-tailed,
two-sample unequal variances Student’s t-test was used to ascertain significance. Viral load expressed in log10 (B). Lung histology collected from IL-6
wild-type and IL-62/2. Samples collected at both day 3 and day 6 pi (C).
doi:10.1371/journal.pone.0038214.g004
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PLoS ONE | www.plosone.org 6 June 2012 | Volume 7 | Issue 6 | e38214distinguishable. Taken together, the results from the IL-62/2
mice compared to IL-6 wild-type mice during H1N1pdm infection
revealed no marked differences in survival, weight loss, or
pathology.
Discussion
Increased IL-6 expression and protracted pulmonary inflam-
mation have been reported in critically ill H1N1pdm infected
patients [6,8,9,25]. We sought to investigate the role of in-
flammatory mediator IL-6 in severe H1N1pdm infection. Among
humans hospitalized with H1N1pdm infection, we found serum
IL-6 levels associated strongly with requirement of critical care
admission and fatal outcome. Consistent with clinical observations,
we found that IL-6 was increased during the host response to
H1N1pdm infection in mice. However, infection of IL-62/2
mice resulted in disease indistinguishable from that in IL-6 wild-
type mice, as measured by survival, weight loss, viral load, and
pathology. Our findings suggest that IL-6 does not play an
essential non-redundant role in the host response to H1N1pdm
infection in mice. Furthermore, these results indicate more
research is needed for the suitability of IL-6 as a therapeutic
target and disease severity biomarker.
Severe H1N1pdm infection in humans is characterized by
extensive pulmonary inflammation which can lead to ARDS and
death [6,8,9]. Clinically, we found that IL-6 levels associated
strongly with disease severity in hospitalized patients which was
also mirrored in three mouse strains, suggesting a potential
mechanism of disease. Cytokine storm is the induction of
a protracted systemic inflammatory response stemming from
cytokine dysregulation [29]. The resulting inflammation can cause
extensive tissue damage, as has been observed during avian
influenza A H5N1 and SARS infection [18,30–32]. IL-6 has been
implicated in both avian influenza A H5N1- and SARS-induced
cytokine storms [16–18,33], and from our data in humans we
hypothesized that IL-6 would have a similar damaging role during
severe H1N1pdm infection.
The genetic background of humans, mice and other animals are
a significant factor leading to the type of immune response
mounted toward pathogens [34–36]. To determine if IL-6
expression following H1N1pdm infection was dependent on the
genetic background of the host, we investigated IL-6 levels in three
mouse strains infected with H1N1pdm: C57BL/6J, BALB/cJ and
B6129SF2/J. Previously, Otte et al. reported that BALB/cJ mice
were less susceptible than C57BL/6J mice to H1N1pdm infection
and speculated that this may be due to dampened cytokine
expression in C57BL/6J mice [26]. In contrast, we found that
C57BL/6J, BALB/cJ, and B6129SF2/J mice were similarly
susceptible to A/Mexico/4108/2009 (H1N1pdm) infection. No
statistically significant differences in disease severity were observed
based on survival, weight loss, or lung viral load, although
B6129SF2/J mouse final percent survival (0%) was markedly
lower than that observed in C57BL/6J (36.4%) and BALB/cJ
(18.2%) mice. Additional experiments, such as LD50 studies, may
reveal significant differences in survival between mouse strains and
clarify the potential genetic determinants of disease severity.
Marked upregulation of IL-6 expression, both at the RNA and
protein levels, was observed in mice of all three genetic back-
grounds. Interestingly, we found C57BL/6J mice to be the
strongest IL-6 producers while BALB/cJ mice were the weakest,
suggesting cytokine responses may not have been dampened in
C57BL/6J mice. Serum IL-6 protein levels were significantly
higher in C57BL/6J mice than in BALB/cJ mice. No other
differences were statistically significant but larger studies may
further resolve differences in IL-6 responses between mouse
strains. In summary, we found from our strain comparison studies
that all three mouse strains had similar virus susceptibility, disease
severity as well as induced levels of IL-6. Our findings implicated
IL-6 in the host response to H1N1pdm in mice and also suggested
C57BL/6J mice to be a suitable genetic background for IL-6
studies.
Global gene expression studies by microarray further under-
lined the importance of IL-6 in C57BL/6J mice as IL-6-mediated
inflammatory response genes were prominently upregulated. Our
microarray experiments were performed at a higher infection dose
than our strain comparison studies (10
5 EID50, compared to 10
4
EID50). Since differences in infection dose could alter gene
expression profiles in infected mice, we also investigated gene
expression by real-time PCR for mice infected with 10
4 EID50.A t
both 10
4 EID50 and 10
5 EID50, we consistently observed
significant upregulation of Il6 mRNA. Furthermore, we found
IL-6 protein levels to be elevated in mice infected with 10
4 EID50.
Taken together, these results suggested a consistent role for IL-6 in
response to H1N1pdm infection at either 10
4 or 10
5 EID50.
To investigate the immune mechanisms of severe H1N1pdm
infection we employed an IL-62/2 mouse model, but did not
observe significant differences in survival or weight loss compared
to wild-type. We also found no differences in viral load or lung
pathology, suggesting IL-6 did not play a direct role in the viral
clearance or in the pathological destruction associated with the
inflammatory process, despite the known proinflammatory roles of
IL-6 [14,15]. Since mice are often used for preliminary testing of
therapeutic candidates for human diseases, results of our mouse
IL-62/2 model suggest targeting IL-6 may not have the intended
therapeutic benefit.
While the IL-62/2 mouse model has repeatedly been used to
identify unique functions of IL-6 in immune responses to infection
[37–40], additional proinflammatory cytokines may drive in-
flammation in the absence of IL-6. Specifically, IL-1b and TNF-
a signalling are negatively regulated by IL-6 [19,41] and may
compensate for the loss of IL-6, which could explain why IL-62/
2 mice were not protected during H1N1pdm infection. The
potentially offsetting contributions of IL-1b and TNF-a in the
absence of IL-6 should be investigated further.
Although C57BL/6J mice were the strongest IL-6 producers in
our strain comparison studies, Otte and colleagues concluded that
C57BL/6J mice are low cytokine producers. With this conclusion
in mind, it is possible that dampened cytokine responses in
C57BL/6J mice could minimize the role of hypercytokinemia
during H1N1pdm infection. IL-6 deficiency in C57BL/6J
background may not have affected survival and/or disease severity
where it would have in another mouse background. Furthermore,
C57BL/6J mice are predisposed to Th1-type immune responses
whereas BALB/cJ mice are predisposed to Th-2 type immune
responses. Although IL-6 deficiency had no effect in Th1-type
skewed C57BL/6J mice, the role of IL-6 could be significantly
different in Th2-type skewed BALB/cJ mice. It is important that
future studies investigate IL-6 deficiency in other mouse strains to
determine what impact host genetic background has on the
protective or pathogenic roles of IL-6.
In humans, we found that serum IL-6 levels were significantly
higher in critically ill hospitalized patients compared to non-
critical patients. Among critically ill patients, we also observed
a trend of increased IL-6 in nonsurvivors compared to survivors.
Similarly, we detected increased IL-6 levels in H1N1pdm-infected
mice, which was associated with disease pathogenesis. Interesting-
ly, BALB/cJ mice were the weakest producers of IL-6. While we
observed no statistical differences in disease severity between
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mice. Taken together, these studies may suggest IL-6 to be an
indicator of disease severity in mice, as we observed in human
patients. IL-6 deficiency did not impact disease outcome in
C57BL/6J mice, but the consistent association of IL-6 with severe
disease suggests host response elements that contribute to disease
may be regulated by a common upstream event which also
governs the IL-6 associated inflammatory response. Thus, IL-6
may serve as a potential disease severity biomarker during
H1N1pdm infection, as IL-6 has been shown to be a biomarker
in other diseases [15,42]. Further investigation is critical to
elucidate the role of IL-6 as a disease severity marker in influenza,
specifically severe H1N1pdm.
Certain medical conditions such as asthma influence the host
immune response and are risk factors for complication in
H1N1pdm infection [6]. IL-6 may contribute differently to the
inflammatory response in individuals with such comorbidities. Our
models did not permit investigation of the role of IL-6 in
individuals with comorbidities since C57BL/6J, BALB/cJ, and
B6129SF2/J genetic backgrounds are all healthy, immunocom-
petent mouse models. Testing the contribution of IL-6 to disease in
mice with underlying comorbidities, such as diabetes, may reveal
roles for IL-6 in H1N1pdm pathogenesis not seen in our healthy
mouse model. It is also possible our findings are limited to our
mouse model and not representative of the host response in
humans, although both species showed significant IL-6 induction
following infection.
Importantly, we have shown increased IL-6 expression in
humans hospitalized with H1N1pdm infection, supported by
prominent IL-6 responses in mouse models of severe H1N1pdm
infection, heavily implicating IL-6 in the host response to
H1N1pdm. Yet, IL-6 deficiency in mice had no significant
bearing on any of the clinical manifestations studied, suggesting
that IL-6 does not play an essential non-redundant role in
H1N1pdm infection in mice. Clinically, our study suggests IL-6
may serve as an important biomarker for the identification of
patients at risk of severe complications following H1N1pdm
infection, but may not be a suitable therapeutic target.
Materials and Methods
Ethics Statement
For clinical studies, written informed consent was obtained
directly from each study participant or their legal representative
before enrolment. Permission to perform scientific studies was
granted by the Comisio ´n de Investigacio ´n del Hospital Clinico
Universitario de Valladolid, Spain. Scientific and ethical approval
of the study protocol was also obtained from the Scientific
Committees for Clinical Research of each one of the participant
centres.
For animal studies, all work was performed in strict accordance
with the Canadian Council of Animal Care guidelines. Animal use
protocols were approved by the Animal Care Committee of the
University Health Network (Toronto, Canada). The University
Health Network is certified under the Animals for Research Act
(Permit Numbers: #0045 and #0085 under the jurisdiction of the
Ontario Ministry of Agriculture, Food, and Rural Affairs) and
follows NIH guidelines (OLAW #A5408-01). All infections and
sample collections were performed under 5% isofluorane anaes-
thesia with every effort made to minimize suffering.
Clinical Sample Collection
Hospitalized patients were recruited during the 2009 pandemic
in ten different hospitals within the National Public Health System
of Spain. Only those patients with confirmed H1N1pdm infection
by qRT-PCR were included in the study. Viral RNA from
nasopharyngeal swabs was obtained using automatic extractors
purchased from either Biome ´rieuxH (Marcy l’Etoile, France) or
RocheH (Basel, Switzerland). Viral presence was then assessed in
the Microbiology Services of the participant hospitals by qRT-
PCR using either the Influenza A (H1N1) MGB Detection Assay
from Applied Biosystems (Carlsbad, CA, USA), provided free of
charge by the Centers for Disease Control (Atlanta, GA, USA), or
the RealTime Ready Influenza A/H1N1 Detection Set from
RocheH (Basel, Switzerland). Patients with signs of bacterial
infection defined by the presence of purulent respiratory
secretions, and/or positive result in respiratory cultures, blood
cultures, and/or positive urinary antigen test to Legionella
pneumophila or Streptococcus pneumoniae were excluded from analysis.
A total of 45 hospitalized patients with laboratory-confirmed
H1N1pdm were enrolled in the study. Patients were divided into
two groups along two different criteria: the requirement of critical
(n=35) or non-critical (n=10) care and survival (n=35) or death
(n=10). A single serum sample was collected from each patient
within 48 hours of hospital admission, according to a unified
protocol for all the participant centers. Samples were adequately
centrifuged and the serum was separated and stored at 280uC
until immune mediator profiling.
Serum IL-6 Measurement
Serum IL-6 levels were measured using the Biorad Luminex
Assay Platform (Hercules, CA, USA) at the Infection & Immunity
Medical Investigation Unit, HCUV-IECSCYL (Valladolid,
Spain).
Animals
Female C57BL/6J, BALB/cJ, B6129SF2/J, and B6.129S2-
Il6
tm1Kopf/J (IL-62/2) mice (8–10 weeks of age) were purchased
from Jackson Laboratories (Bar Harbor, MN, USA) and used in
influenza studies. Notably, B6.129S2-Il6
tm1Kopf/J (IL-62/2) were
generated from C57BL/6J blastocysts and bred to C57BL/6J mice
for 11 generations. Mice were maintained on standard animal feed
and water ad libitum in clean environmental conditions and
controlled temperature and humidity with a 12 hour light and
dark cycle. For infection studies, animals were housed in HEPA-
filtered cage racks adherent to ABSL2+ conditions (Toronto
General Hospital Animal Resource Centre, Toronto, Canada). All
animal procedures were performed in a certified class II biosafety
cabinet (Baker Company, Sanford, NC, USA).
Viral Infection
All infection experiments were conducted with H1N1pdm
strain, A/Mexico/4108/2009 (H1N1pdm), provided by the
Centers for Disease Control and Prevention (Atlanta, GA, USA).
Virus was propagated and titrated in embryonated eggs prior to
animal challenge. Viral stocks were stored in liquid nitrogen and
thawed prior to use. Mice (either C57BL/6J, BALB/cJ,
B6129SF2/J, or IL-62/2) were weighed and randomly assigned
for sample collection. Mice were infected through intranasal
instillation with 50 mL phosphate-buffered saline (mock infection)
or 50 mL A/Mexico/4108/2009 (H1N1pdm) at 1610
5 or 1610
4
50% egg infectious dose (EID)50. Virus dosage was 1610
5 EID50
for host response profiling in C57BL/6J mice and 1610
4 EID50
for comparing disease severity between C57BL/6J, BALB/cJ, and
B6129SF2/J mice, as well as between C57BL/6J and IL-62/2
mice. Throughout infection experiments, animal survival, clinical
signs, and weights were recorded daily. In accordance with Animal
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recorded body weight fell below 80% of original body weight.
Viral Load Measurement
At days 0 and 3 pi, mice (n=3) were euthanized and lung
homogenates collected for viral load determination. Lungs were
homogenized (10% w/v) in High Glucose (4.5 g/L) Dulbecco’s
Modified Eagle Medium (DMEM), supplemented with 1% bovine
serum albumin, 50 mg/mL Gentamycin, 100 U/mL Penicillin,
100 mg/mL Streptomycin, and 1 mg/mL TPCK-Trypsin
(vDMEM). Homogenates were then serially diluted (0.5 log10)i n
quadruplicate over Madin-Darby Canine Kidney cells, cultured at
2.0610
4 cells/well in 96-well plates. Cells were incubated for 2
hours at 37uC and 5% CO2. Homogenates were then removed
and replaced with fresh vDMEM. Cells thus infected were
incubated for 6 days at 37uC and 5% CO2, after which cell
culture supernatants were tested for the presence of virus by
hemagglutination assay using 0.5% (v/v) turkey red blood cells
(LAMPIRE Biological Laboratories, Pipersville, PA, USA). Viral
loads were determined as the reciprocal of the dilution at which
50% of wells were positive for viral infection. Viral loads were
reported as TCID50 per gram of lung tissue. Limit of detection of
10
1.75 TCID50/g.
Cytokine Protein Measurement
At days 0 and 5 pi, lung tissues and serum were collected for
cytokine measurement (n=3 for each). Lungs were homogenized
(10% w/v) in High Glucose (4.5 g/L) DMEM supplemented with
cOmplete EDTA-free protease inhibitor cocktail (Roche Applied
Science, Laval, Canada). Cytokine levels, including IL-6, were
measured by cytokine bead array Mouse Inflammation Kit (BD
Biosciences, San Diego, CA, USA), as per manufacturer’s
instructions.
Host Gene Expression Measurement by qRT-PCR
Total lung tissue RNA was reverse transcribed using ImProm-II
Reverse Transcription System (Promega, Madison, WI, USA).
qRT-PCR was performed using the ABI-Prism 7900HT Sequence
Detection Systems (Applied Biosystems, Foster City, CA, USA).
Raw data was collected with Applied Biosystems Sequence
Detection Systems Version 2.2 software. Each reaction well
contained 0.25 mL of 20 ng/uL cDNA, 0.5 mL each of forward
and reverse primers (final concentration of 200 nM), and 5 mL
SYBR Green Master Mix, for a total reaction volume of 10 uL.
Each sample was run in quadruplicate. Gene expression was
normalized to the b-actin housekeeping gene, and quantified by
the relative standard curve method. Primer sequences are listed in
Table S2.
Microarray Analysis
At designated time points (ie. days 0 through 6 pi), C57BL/6J
mice were euthanized (n=3) and lung tissue was collected. Total
RNA was amplified with Illumina TotalPrep RNA Amplification
Kit (Ambion, Austin, TX, USA) as per manufacturer’s instruc-
tions. cRNA (1.5 mg) was labelled and hybridized to MouseWG-6
v2.0 Expression BeadChip (Illumina, San Diego, CA, USA) and
scanned on Illumina BeadStation 500GX. Raw data was collected
with Illumina GenomeStudio V2010.3 software. The data sets
were pre-processed with quantile normalization, variance stabili-
zation, and log2 transformation. Time series analysis was
performed with Extraction of Differential Gene Expression
(EDGE) software (Storey Lab, University of Washington, WA,
USA). Benjamini-Hochberg correction was employed to assess the
occurrence of false positives by calculating the false discovery ratio.
Hierarchical clustering by Pearson’s correlation and heatmap
representations were generated using MultiExperiment Viewer
v4.6.2 (Dana-Farber Cancer Institute, Boston, MA, USA). In-
genuity Pathway Analysis v9.0 (IPA) (Ingenuity Systems, Redwood
City, CA, USA) was used to select, annotate and visualize genes by
function and pathway. DAVID Bioinformatics Resource v6.7
[27,28] was also used to perform functional classification of
differentially expressed genes.
Histology
C57BL/6J mice and IL-62/2 mice were euthanized at day 3
(n=3) and day 6 (n=1) pi and harvested lung tissues were
perfused with 10% buffered formalin. Tissues were paraffin wax
embedded for histology. Sections were stained with Hematoxylin
and Eosin and observed under light microscope (Accu-scopeH,
Commack, NY, USA). Images were captured using a digital
camera and SE Premium software (Micrometrics
TM, London-
derry, NH, USA).
Microarray Data Accession Number
Microarray expression data are MIAME compliant and are
available publicly in the MIAME-compliant Gene Expression
Omnibus database (www.ncbi.nlm.nih.gov/geo/) under accession
number GSE31022.
Statistical Methods
For clinical patient data, serum IL-6 levels were compared using
the Mann-Whitney U test (a=0.05). BLR analysis was employed
to predict the probability of critical care admission and death as
a function of IL-6 (log10 IL-6 (pg/mL)) levels, adjusted by age and
sex. Both age and sex were identified as confounding variables
when investigating the relationship between IL-6 levels and disease
severity. Adjustment was performed by incorporating age and sex
as predictors in the logistic regression model, thereby minimizing
the confounding effect of these variables. The Student’s t-test
(a=0.05) was used to identify statistically significant increases in
expression of genes assayed by qRT-PCR. Survival curves were
compared by the logrank test (a=0.05) [43]. Comparisons of
weight loss, viral load, gene fold change in expression, and
cytokine expression were also made using the Student’s t-test
(a=0.05). All Student’s t-tests assumed two-tailed distributions
and two-sample unequal variances.
Supporting Information
Figure S1 Mortality and weight loss in C57BL/6J mice
infected A/Mexico/4108/2009 (H1N1pdm). Survival curve
for C57BL/6J mice infected intranasally with 10
5 EID50 A/
Mexico/4108/2009 (H1N1pdm). n=35 (A). Average weight
curve for C57BL/6J mice infected intranasally with 10
5 EID50
A/Mexico/4108/2009 (H1N1pdm). Vertical error bars indicate
61 standard deviation for the average weight at each time point.
n=35 (B).
(TIF)
Table S1 Increased expression of acute inflammatory
response genes in C57BL/6J mice infected with A/
Mexico/4108/2009 (H1N1pdm). DAVID Bioinformatics
Resource v6.7 [27,28] was applied to all differentially expressed
genes for classification. Gene Ontology Biological Process pathway
GO:0002526 – acute inflammatory response was selected as
a suitable representation of genes implicated in the acute phase
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0 values normalized to 0.
(DOC)
Table S2 Sequences of primers used for qRT-PCR.
(DOC)
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